Table 9.

Independent cohorts.

GEO	45255 (ch)	45255 (ho)	45255 (chho)	37181	7390	2034
End point	os	os	os	dfs	os	rfs
Therapy	No-yes-no	No-no-yes	No-yes-yes	No-no-no	No-no-no	Yes-no-no
n.p.	8	16	13	119	181	264
$>5y$	3	6	4	59	24	95
$<5y$	5	10	9	60	157	169
n.a.	8	16	13	106	179	258
Kappa	1.0	0.58	1.0	0.35	0.36	0.12
Sen.	1.0	0.8	1.0	0.66	0.7	0.90
Spe.	1.0	0.81	1.0	0.70	0.89	0.67
OR	15.0	18.0	36.0	4.59	20.86	20.12
CI-Lo	0.66	1.24	1.77	2.01	4.93	2.53
CI-Hi	339	260	731	10	88.2	159
OR p-val	0.19	0.03	0.01	3.7E−4	3.0E−5	1.8E−4
AUC	1.0	0.89	1.0	0.72	0.70	0.63
AUC p-val	0.01	0.005	0.003	2.6E−5	7.5E−4	1.0E−4

Results of leave-one-out evaluation with optimal multigene fingerprints derived from Metabric data sets. Therapy class: (RAD, CHE, HOR). Endpoint (e.p.) is os overall survival, dfs disease-free survival, rfs relapse-free survival. Confidence interval for odds ratio at 95% confidence. n.a. number of answers.